Clinical Trials · NCT05646706
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,407
- Start date
- Jan 2023
- Locations
- 107 sites, 12 countries
- Primary endpoint
- Semaglutide 7.2 mg Versus Placebo: Relative Change in Body Weight